These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26553675)

  • 1. Lessons Learned From Enhancing Vaccine Pharmacovigilance Activities During PsA-TT Introduction in African Countries, 2010-2013.
    Diomandé FV; Yaméogo TM; Vannice KS; Preziosi MP; Viviani S; Ouandaogo CR; Keita M; Djingarey MH; Mbakuliyemo N; Akanmori BD; Sow SO; Zuber PL
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S459-66. PubMed ID: 26553675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Active Surveillance for Adverse Events After a Mass Vaccination Campaign With a Group A Meningococcal Conjugate Vaccine (PsA-TT) in Mali.
    Vannice KS; Keita M; Sow SO; Durbin AP; Omer SB; Moulton LH; Yaméogo TM; Zuber PL; Onwuchekwa U; Sacko M; Diomandé FV; Halsey NA
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S493-500. PubMed ID: 26553680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact After the Introduction of PsA-TT: The First 4 Years.
    Diomandé FV; Djingarey MH; Daugla DM; Novak RT; Kristiansen PA; Collard JM; Gamougam K; Kandolo D; Mbakuliyemo N; Mayer L; Stuart J; Clark T; Tevi-Benissan C; Perea WA; Preziosi MP; Marc LaForce F; Caugant D; Messonnier N; Walker O; Greenwood B
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S467-72. PubMed ID: 26553676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
    Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring adverse events following immunization with a new conjugate vaccine against group A meningococcus in Niger, September 2010.
    Chaibou MS; Bako H; Salisou L; Yaméogo TM; Sambo M; Kim SH; Djingarey MH; Zuber PL; Perea WA; Pezzoli L
    Vaccine; 2012 Jul; 30(35):5229-34. PubMed ID: 22709955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Yakum MN; Mengouo MN; Genton B
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1170-1178. PubMed ID: 27174237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3, Double-Blind, Randomized, Active Controlled Study to Evaluate the Safety of MenAfriVac in Healthy Malians.
    Tapia MD; Sow SO; Haidara FC; Diallo F; Doumbia M; Enwere GC; Paranjape G; Hervé J; Bouma E; Parulekar V; Martellet L; Chaumont J; Plikaytis BD; Tang Y; Kulkarni PS; Hartmann K; Preziosi MP
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S507-13. PubMed ID: 26553682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.
    Dellepiane N; Akanmori BD; Gairola S; Jadhav SS; Parker C; Rodriguez C; Srivastava S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S428-33. PubMed ID: 26553671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
    Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 'SAEFVIC', A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia.
    Clothier HJ; Crawford NW; Russell M; Kelly H; Buttery JP
    Drug Saf; 2017 Jun; 40(6):483-495. PubMed ID: 28342074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Safety of PsA-TT in Pregnancy: An Assessment Performed Within the Navrongo Health and Demographic Surveillance Site in Ghana.
    Wak G; Williams J; Oduro A; Maure C; Zuber PL; Black S
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S489-92. PubMed ID: 26553679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
    Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
    Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines safety; effect of supervision or SMS on reporting rates of adverse events following immunization (AEFI) with meningitis vaccine (MenAfriVac™): a randomized controlled trial.
    Ateudjieu J; Stoll B; Nguefack-Tsague G; Tchangou C; Genton B
    Vaccine; 2014 Sep; 32(43):5662-8. PubMed ID: 25160064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine pharmacovigilance in South Africa: successes and limitations of current approaches.
    Peter J; Takalani A; Meyer JC; Semete-Makokotlela B; Collie S; Seocharan I; Goga A; Garrett N; Gail-Bekker L; Gray G
    Expert Opin Drug Saf; 2024 Oct; 23(10):1215-1225. PubMed ID: 39115010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allergic reactions to Japanese encephalitis vaccine.
    Plesner AM
    Immunol Allergy Clin North Am; 2003 Nov; 23(4):665-97. PubMed ID: 14753386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal carriage in the African meningitis belt.
    MenAfriCar Consortium
    Trop Med Int Health; 2013 Aug; 18(8):968-78. PubMed ID: 23682910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.